Safety Study of an Oral Vitamin D Analog in Postmenopausal Women

Phase 1 Completed Deltanoid Pharmaceuticals

Determine the safety of 2MD, a vitamin D analog, when administered orally once daily for 28 days in healthy normal postmenopausal women.

Evaluation	Drug	Modality	Dose	Route
Subject	2MD	Unknown	50 ng	Oral
Subject	2MD	Unknown	110 ng	Oral
Subject	2MD	Unknown	170 ng	Oral
Subject	2MD	Unknown	220 ng	Oral
Subject	2MD	Unknown	440 ng	Oral
Comparator	Calcitriol	Small molecule	—	—